264 related articles for article (PubMed ID: 32974856)
1. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
2. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Herrington JD; Dinh BC
J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
4. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
7. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
8. Low-dose rasburicase in hematologic malignancies.
Jayabose S; Kumar V; Dhanabalan R; Rajan P; Rathnam K; Viswanathan TK
Indian J Pediatr; 2015 May; 82(5):458-61. PubMed ID: 25338496
[TBL] [Abstract][Full Text] [Related]
9. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
[TBL] [Abstract][Full Text] [Related]
10. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
[TBL] [Abstract][Full Text] [Related]
11. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
[TBL] [Abstract][Full Text] [Related]
12. Rasburicase in the prevention and treatment of tumour lysis syndrome.
Mayne N; Keady S; Thacker M
Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Eng S; Lee CS; Ahn S; Sharma A
J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
[TBL] [Abstract][Full Text] [Related]
14. Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
Agrawal AK; Feusner JH
Br J Haematol; 2011 Apr; 153(2):275-7. PubMed ID: 21255003
[No Abstract] [Full Text] [Related]
15. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Kennedy LD; Ajiboye VO
J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
19. Treatment of impending tumor lysis with single-dose rasburicase.
Lee AC; Li CH; So KT; Chan R
Ann Pharmacother; 2003 Nov; 37(11):1614-7. PubMed ID: 14565793
[TBL] [Abstract][Full Text] [Related]
20. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Patel KS; Lau JE; Zembillas AS; Gallagher EM
J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
